Kupiec-Weglinski J W, Wasowska B, Papp I, Schmidbauer G, Sayegh M H, Baldwin W M, Wieder K J, Hancock W W
Harvard Medical School, Department of Surgery, Boston, MA 02115.
J Immunol. 1993 Nov 1;151(9):5053-61.
The accelerated (24 h) rejection of (LEWxBN)F1 cardiac allografts (Tx) in LEW rats sensitized with BN skin grafts, is abrogated with CD4 mAb (BWH-4) administration between skin (day -7) and heart (day 0) transplantation (Tx survival ca. 11 days, p < 0.0001). This study analyzed the effects of CD4-targeted therapy upon host IgG and IgM alloantibody (allo-Ab) within the serum by two-color flow cytometry, and within the Tx, by immunohistology. These data were correlated with mRNA and protein production profiles of Th1 (IL-2, IFN-gamma) vs Th2 (IL-4) specific cytokines (polymerase chain reaction and/or immunohistology). Skin grafts elicited a strong systemic IgM allo-Ab response, which peaked at the time of cardiac Tx rejection at 24 h. It was associated with extensive deposits of IgM on Tx endothelium. Treatment with BWH-4 mAb diminished circulating IgM allo-Ab levels, and only low levels of IgM could be detected at the Tx site. Conversely, the low circulating IgG allo-Ab levels during rejection at 24 h in untreated recipients were accompanied by a strong labeling for intra-Tx IgG. BWH-4 mAb therapy did not prevent totally the switch of the IgM to IgG, but the IgG allo-Ab response was earlier, less intense and more transient than in untreated recipients. Accelerated rejection triggered sequential lymphokine mRNA expression in cardiac Tx, with the peak of transcription for IL-2 (6-12 h) preceding that for IL-4 (24 h). Interestingly, although CD4 targeted therapy virtually ablated the induction of IL-2 mRNA, it preserved transcription of the IL-4 gene. BWH-4 mAb therapy decreased otherwise abundant intra-Tx IL-2 and IFN-gamma, but allowed a vigorous elaboration of IL-4, confirming the translation of mRNA to the protein in vivo. Thus, CD4 mAb-mediated abrogation of accelerated cardiac Tx injury correlates with suppression of Th1 responses (depressed IL-2 and IFN-gamma production), but sparing of the Th2 function (enhanced IL-4 elaboration). Indeed, CD4 mAb-induced allo-Ab depression and immunosuppressive effects may reflect selective targeting of proinflammatory Th1-like cells and the multifaceted effects of IL-4 produced by unopposed Th2-like cells.
用BN皮肤移植物致敏的LEW大鼠中,(LEWxBN)F1心脏异体移植物(Tx)的加速(24小时)排斥反应,在皮肤移植(第-7天)和心脏移植(第0天)之间给予CD4单克隆抗体(BWH-4)后被消除(Tx存活约11天,p<0.0001)。本研究通过双色流式细胞术分析了CD4靶向治疗对血清中宿主IgG和IgM同种异体抗体(同种抗体)的影响,并通过免疫组织学分析了对Tx内同种抗体的影响。这些数据与Th1(IL-2、IFN-γ)与Th2(IL-4)特异性细胞因子的mRNA和蛋白质产生谱相关(聚合酶链反应和/或免疫组织学)。皮肤移植引发了强烈的全身性IgM同种抗体反应,在心脏Tx排斥反应的24小时达到峰值。这与Tx内皮上大量的IgM沉积有关。用BWH-4单克隆抗体治疗可降低循环中的IgM同种抗体水平,在Tx部位仅能检测到低水平的IgM。相反,未经治疗的受体在24小时排斥反应期间循环中低水平的IgG同种抗体伴随着Tx内IgG的强烈标记。BWH-4单克隆抗体治疗并未完全阻止IgM向IgG的转换,但IgG同种抗体反应比未经治疗的受体更早、更弱且更短暂。加速排斥反应引发心脏Tx中连续的淋巴因子mRNA表达,IL-2(6-12小时)的转录峰值先于IL-4(24小时)。有趣的是,尽管CD4靶向治疗实际上消除了IL-2 mRNA的诱导,但它保留了IL-4基因的转录。BWH-4单克隆抗体治疗降低了Tx内原本丰富的IL-2和IFN-γ,但允许IL-4大量产生,证实了mRNA在体内向蛋白质的转化。因此,CD4单克隆抗体介导的加速心脏Tx损伤的消除与Th1反应的抑制(IL-2和IFN-γ产生减少)相关,但保留了Th2功能(IL-4产生增强)。事实上,CD4单克隆抗体诱导的同种抗体抑制和免疫抑制作用可能反映了对促炎性Th1样细胞的选择性靶向以及未受抑制的Th2样细胞产生的IL-4的多方面作用。